LimmaTech Biologics AG
🇨ðŸ‡Switzerland
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.lmtbio.com
A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.
Phase 1
Recruiting
- Conditions
- Staphylococcus (S.) Aureus Infection
- Interventions
- Biological: LTB-SA7Biological: Placebo
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- LimmaTech Biologics AG
- Target Recruit Count
- 129
- Registration Number
- NCT06719219
- Locations
- 🇺🇸
Naval Medical Research Command Clinical Trial Center, Bethesda, Maryland, United States
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
Phase 2
Recruiting
- Conditions
- Shigellosis
- Interventions
- Biological: Shigella4V2Biological: Placebo
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- LimmaTech Biologics AG
- Target Recruit Count
- 120
- Registration Number
- NCT06615375
- Locations
- 🇺🇸
Hope Clinic of Emory University, Atlanta, Georgia, United States
Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.
Phase 2
Not yet recruiting
- Conditions
- Shigellosis
- Interventions
- Biological: Shigella4V2Biological: MenACWY
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- LimmaTech Biologics AG
- Target Recruit Count
- 110
- Registration Number
- NCT06523231
- Locations
- 🇰🇪
KEMRI - Center for Global Health Research, Kisumu, Kenya
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: a Randomized Controlled Study
Phase 1
Recruiting
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Biological: Vaccine
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- LimmaTech Biologics AG
- Target Recruit Count
- 251
- Registration Number
- NCT06190509
- Locations
- 🇧🇪
Femicare, Tienen, Belgium
Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V)
Phase 1
Completed
- Conditions
- Klebsiella Pneumoniae Infection
- Interventions
- Biological: Kleb4V low doseBiological: Kleb4V low dose + AS03Biological: Kleb4V target dose + AS03Biological: PlaceboBiological: Kleb4V target dose
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- LimmaTech Biologics AG
- Target Recruit Count
- 166
- Registration Number
- NCT04959344
- Locations
- 🇩🇪
Nuvisan GmbH, Standort Gauting, Robert-Koch-Allee 29, Gauting, Germany
🇩🇪Nuvisan GmbH, Standort Neu-Ulm, Wegenerstrasse 13, Neu-Ulm, Germany
A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
Phase 1
Completed
- Conditions
- Shigellosis
- Interventions
- Biological: Shigella 4VBiological: RabiesBiological: MenACWYBiological: Diphtheria, Tetanus and Pertussis (DTaP)Biological: Placebo
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- LimmaTech Biologics AG
- Target Recruit Count
- 596
- Registration Number
- NCT04056117
- Locations
- 🇰🇪
KEMRI-Centre Geographic Medical Research-COAST (KEMRI-CGMRC), Kilifi, Kenya
🇰🇪Kenya Medical Research Institute (KEMRI)/ United States Army Medical Research Directorate- Kenya (USAMRD-K), Kericho, Kenya
Phase I to Test a New Pneumococcal Vaccine
Phase 1
Completed
- Conditions
- Pneumonia, BacterialPneumococcal Pneumonia
- Interventions
- Biological: Bioconjugate pneumococcal vaccineBiological: Multivalent plain polysaccharide vaccine
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- LimmaTech Biologics AG
- Target Recruit Count
- 72
- Registration Number
- NCT03303976
- Locations
- 🇩🇪
CRS, Mönchengladbach, Germany
Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a
Phase 2
Completed
- Conditions
- Shigellosis
- Interventions
- Biological: Flexyn2aBiological: Placebo
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- LimmaTech Biologics AG
- Target Recruit Count
- 67
- Registration Number
- NCT02646371
- Locations
- 🇺🇸
Johns Hopkins Bloomberg School of Public Health, CIR, Baltimore, Maryland, United States
Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a
Phase 1
Completed
- Conditions
- Shigellosis
- Interventions
- Biological: Flexyn2aBiological: Flexyn2a plus adjuvantBiological: Placebo
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- LimmaTech Biologics AG
- Target Recruit Count
- 30
- Registration Number
- NCT02388009
- Locations
- 🇺🇸
WRAIR Clinical Trial Center (CTC), Silver Spring, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath